Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraductal Liposomal Bupivacaine for Chronic Pancreatitis Pain
NCT04611958Phase 1Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Jul 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupivacaine extended release liposome injection in chronic pancreatitis (CP), sponsored by Johns Hopkins University. Primary endpoint: Change in the pain score at 24 hours. Planned start Jul 2021; status: withdrawn.
02
Drugs
bupivacaine extended release liposome injection
03
Conditions
chronic pancreatitis (CP)
Beyond the preview
Go deeper on NCT04611958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611958.